drugset
drugset / Trial / NCT07650383

A Study to Evaluate ENERGI-F705 Tablets in Healthy Volunteers

NCT07650383 ↗

Phase 1 Completed 24 enrolled Energenesis Biomedical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety, the tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of ENERGI-F705 Tablets in healthy subjects.

Timeline

Start
2025-02-24
Primary completion
2025-05-06
Completion
2025-11-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator ENERGI-F705 Unknown 60 mg Oral
Comparator ENERGI-F705 Unknown 120 mg Oral

Indications

No indication recorded.